Protocol Ledger

NCT07395232 · Phase III · RECRUITING

An Efficacy and Safety Study of DFL24498 in the Treatment of AKC

Interventional Phase III clinical trial protocol NCT07395232 sponsored by Dompé Farmaceutici S.p.A in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-12-01 Enrollment: 153 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07395232
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)153 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07395232
Protocol FieldVerified Registry Value
NCT IdentifierNCT07395232
Consolidated Lead SponsorDompé Farmaceutici S.p.A
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment153 participants (ESTIMATED)
Registered Start Date2025-12-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07395232
Hospital Research SiteLocationSite Profile
NYU Langone Health and Perlmutter Cancer CenterNew York, NYOpen Hospital Dossier ->
Azienda Ospedaliero Universitaria CareggiFlorence, ItalyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI